What happened
Hengrui Medicine announced it received clinical trial approval notices from China's drug regulator for HRS-6209 capsules and HRS-4508 tablets, allowing the company to proceed with clinical studies.
HRS-6209 will be studied in a Phase Ib/II trial for advanced unresectable or metastatic breast cancer or advanced solid tumors, in combination with other anti-tumor therapies.
HRS-4508 is a novel selective tyrosine kinase inhibitor, while HRS-6209 is a selective CDK4 inhibitor designed to improve blood toxicity compared to existing CDK4/6 inhibitors.
Why it matters
HRS-6209 is a novel selective CDK4 inhibitor with no similar products approved globally, potentially offering a safer alternative to current CDK4/6 inhibitors.
HRS-4508 targets a class where existing drugs have shown commercial success, with one competitor's global sales reaching $463 million in 2025, indicating market potential.
The combined R&D investment of about 258 million yuan underscores Hengrui's commitment to advancing oncology treatments.
Key facts
Hengrui received clinical trial approval for HRS-6209 capsules and HRS-4508 tablets.
HRS-6209 is a new selective CDK4 inhibitor, with no similar products approved globally.
HRS-4508 is a new selective tyrosine kinase inhibitor; similar drugs include tucatinib, which had global sales of about $463 million in 2025.
Cumulative R&D investment for the two drugs totals about 258 million yuan.
What to watch next
Clinical trial results for HRS-6209, especially its safety and efficacy in combination therapy.
Regulatory progress and potential market entry for HRS-4508, given the competitive landscape.
Further pipeline developments from Hengrui in oncology.